Impact of Baseline Synchronous Adenoma Burden on the Risk of Metachronous Advanced Neoplasia
Authors:
- Wei-Yuan ChangWCWei-Yuan Chang
- Li-Chun ChangLCLi-Chun Chang
- Chu-Kuang ChouCCChu-Kuang Chou
- Cheng-Hao TsengCTCheng-Hao Tseng
- Chi-Yang ChangCCChi-Yang Chang
- Chi-Yi ChenCCChi-Yi Chen
- Wen-Feng HsuWHWen-Feng Hsu
- Yen-Nien ChenYCYen-Nien Chen
- Chieh-Chang ChenCCChieh-Chang Chen
- Chia-Hung TuCTChia-Hung Tu
- Mei-Jyh ChenMCMei-Jyh Chen
- Ching-Tai LeeCLChing-Tai Lee
Open Access
- 3 September 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Abstract
INTRODUCTION: and study aim: Individuals classified as high-risk at initial colonoscopy face an elevated risk of metachronous advanced colorectal neoplasms (meta-ACRN), but risk heterogeneity within this group remains unclear. We aimed to stratify meta-ACRN risk among high-risk individuals based on their synchronous neoplastic burden. METHODS: This prospective cohort study used data from a Taiwanese multicenter trial (NCT03373136). We included participants with conventional high-risk findings (3–10 low-risk adenomas [LRAs] or any high-risk adenoma [HRA]). The primary outcome was meta-ACRN incidence. Adjusted incidence rate ratios (aIRRs) were calculated using multivariable Poisson regression, stratifying patients by baseline synchronous burden, with the 3–4 LRAs group as reference. RESULTS: Among 730 participants undergoing surveillance (mean follow-up 2.4 years), 81 (11.1%) developed meta-ACRN. A single HRA did not significantly increase meta-ACRN risk compared with 3–4 LRAs (aIRR 2.02; 95% confidence interval (CI) 0.83–4.90). However, risk escalated significantly when the index HRA was accompanied by synchronous LRA(s) (aIRR 2.56; 95% CI 1.24–5.39) or synchronous HRA(s) (aIRR 3.93; 95% CI 1.77–8.73) ( P for trend = 0.001). Furthermore, applying a more severe modified advanced adenoma criteria, an identical dose-response pattern emerged, culminating in a >5-fold increased risk of severe metachronous outcomes (aIRR 5.23; 95% CI 1.50–18.22) when accompanied by synchronous HRA(s). DISCUSSION: Meta-ACRN risk within the conventional high-risk population is highly heterogeneous and driven primarily by baseline synchronous neoplastic burden. Surveillance intervals should be personalized, reserving shorter intervals for patients with advanced lesions accompanied by synchronous adenomas.Keywords
Funding Information
- National Science and Technology Council (NSTC 113-2640-B-002-005)
- E-Da Hospital (EDAHS114034)
This publication has 27 references indexed in Scilit:
- Risk of metachronous advanced neoplasia was comparable between patients with 1–2 and 3–4 non-advanced adenomas removed during screening colonoscopySurgical Endoscopy, 2026
- Risk for Metachronous Advanced Neoplasia in Patients With a Modified Definition of Advanced Adenoma: Data From the New Hampshire Colonoscopy RegistryClinical Gastroenterology and Hepatology, 2025
- Yield of Advanced Neoplasia at Second Post-polypectomy Surveillance Colonoscopy: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2025
- Quality indicators for colonoscopyGastrointestinal Endoscopy, 2024
- Risk Factors for Metachronous Colorectal Cancer or Advanced Adenomas After Endoscopic Resection of High-risk AdenomasClinical Gastroenterology and Hepatology, 2022
- Risk factors for metachronous adenoma in the residual colon of patients undergoing curative surgery for colorectal cancerInternational Journal of Colorectal Disease, 2017
- Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence toolGastrointestinal Endoscopy, 2017
- Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal CancerGastroenterology, 2012
- A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic PolypectomyGastroenterology, 2009
- The colorectal adenoma–carcinoma sequenceBritish Journal of Surgery, 2002